E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
According to CDSCO, enclomiphene and its combinations have not been approved by the CLA for manufacture and marketing in India.
imphoenix82
The action follows Risk-Based Inspections conducted by CDSCO as part of its oversight of clinical trials across India, which uncovered significant deficiencies in the functioning of these Ethics Committees.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
